MSIF’s international working group on access, in which MPP participated, met in July to advance the global agenda on access to treatments. One of the suggested actions from the meeting is that “the MS Community should collaborate with the MPP, sharing MS-specific expertise and data where necessary, to evaluate opportunity for access-oriented licensing for certain MS drugs (e.g. cladribine) to facilitate availability of quality assured generic medicines and price reductions through generic competition.”

Access the full meeting report

Access MSIF’s article on the meeting “The next steps for improving access to treatments around the world“